Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals logo
GBX 61.50 +1.50 (+2.50%)
As of 03:17 AM Eastern

BXP vs. VEC, SER, ERGO, BMY, and AMYT

Should you buy Beximco Pharmaceuticals stock or one of its competitors? Beximco Pharmaceuticals's main competitors and comparable companies include Vectura Group (VEC), 5533861 (SER.L) (SER), Ergomed (ERGO), Bloomsbury Publishing (BMY), and Amryt Pharma (AMYT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Beximco Pharmaceuticals compare to Vectura Group?

Vectura Group (LON:VEC) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Beximco Pharmaceuticals has higher revenue and earnings than Vectura Group. Vectura Group is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60M0.00N/A£20.10N/A
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03

In the previous week, Vectura Group's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vectura Group Neutral
Beximco Pharmaceuticals Neutral

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Beximco Pharmaceuticals has a net margin of 16.93% compared to Vectura Group's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 15.99% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Vectura GroupN/A N/A N/A
Beximco Pharmaceuticals 16.93%15.99%6.97%

Summary

Beximco Pharmaceuticals beats Vectura Group on 7 of the 8 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to 5533861 (SER.L)?

5533861 (SER.L) (LON:SER) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Beximco Pharmaceuticals has higher revenue and earnings than 5533861 (SER.L).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
5533861 (SER.L)£973.63M0.91N/AN/AN/A
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03

26.6% of 5533861 (SER.L) shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 14.3% of 5533861 (SER.L) shares are owned by insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, 5533861 (SER.L)'s average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
5533861 (SER.L) Neutral
Beximco Pharmaceuticals Neutral

5533861 (SER.L) presently has a consensus target price of GBX 320, suggesting a potential upside of 40.97%. Given 5533861 (SER.L)'s stronger consensus rating and higher probable upside, analysts plainly believe 5533861 (SER.L) is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Beximco Pharmaceuticals has a net margin of 16.93% compared to 5533861 (SER.L)'s net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 15.99% beat 5533861 (SER.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
5533861 (SER.L)N/A N/A N/A
Beximco Pharmaceuticals 16.93%15.99%6.97%

Summary

5533861 (SER.L) beats Beximco Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Ergomed?

Ergomed (LON:ERGO) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Ergomed's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ergomed Neutral
Beximco Pharmaceuticals Neutral

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 18.2% of Ergomed shares are owned by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Ergomed. Ergomed is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£152.09M0.00£15M£0.29N/A
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03

Ergomed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, indicating that its stock price is 75% less volatile than the broader market.

Beximco Pharmaceuticals has a net margin of 16.93% compared to Ergomed's net margin of 9.87%. Ergomed's return on equity of 18.08% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ergomed9.87% 18.08% 10.16%
Beximco Pharmaceuticals 16.93%15.99%6.97%

Summary

Ergomed beats Beximco Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Bloomsbury Publishing?

Bloomsbury Publishing (LON:BMY) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Beximco Pharmaceuticals has a net margin of 16.93% compared to Bloomsbury Publishing's net margin of 6.35%. Beximco Pharmaceuticals' return on equity of 15.99% beat Bloomsbury Publishing's return on equity.

Company Net Margins Return on Equity Return on Assets
Bloomsbury Publishing6.35% 9.42% 7.82%
Beximco Pharmaceuticals 16.93%15.99%6.97%

Beximco Pharmaceuticals has higher revenue and earnings than Bloomsbury Publishing. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bloomsbury Publishing£318M1.62£37.37M£24.5925.87
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03

42.3% of Bloomsbury Publishing shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 3.7% of Bloomsbury Publishing shares are owned by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Bloomsbury Publishing's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bloomsbury Publishing Neutral
Beximco Pharmaceuticals Neutral

Bloomsbury Publishing currently has a consensus price target of GBX 792.50, indicating a potential upside of 24.58%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bloomsbury Publishing is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bloomsbury Publishing
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Bloomsbury Publishing has a beta of 0.418, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, meaning that its stock price is 75% less volatile than the broader market.

Summary

Bloomsbury Publishing beats Beximco Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Amryt Pharma?

Beximco Pharmaceuticals (LON:BXP) and Amryt Pharma (LON:AMYT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Amryt Pharma'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Amryt Pharma Neutral

Beximco Pharmaceuticals has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03
Amryt Pharma£210.24M0.00N/A-£33.00N/A

Beximco Pharmaceuticals has a net margin of 16.93% compared to Amryt Pharma's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 15.99% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.93% 15.99% 6.97%
Amryt Pharma N/A N/A N/A

Summary

Beximco Pharmaceuticals beats Amryt Pharma on 8 of the 8 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

MetricBeximco PharmaceuticalsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£274.36M£13.61B£7.74B£2.79B
Dividend Yield5.99%2.58%2.46%5.11%
P/E Ratio0.0329.4134.1723.17
Price / Sales0.007.028.485.10
Price / CashN/A15.7421.9320.23
Price / Book0.015.114.372.48
Net Income£970.84B£2.88B£3.52B£5.88B
7 Day Performance-0.81%-4.11%-5.47%-1.22%
1 Month Performance15.06%-5.09%-4.58%-2.86%
1 Year Performance51.85%-7.45%-1.79%6.43%

Beximco Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BXP
Beximco Pharmaceuticals
N/AGBX 61.50
+2.5%
N/A+41.1%£274.36M£56.27B0.035,500
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200
SER
5533861 (SER.L)
N/AGBX 227
flat
GBX 320
+41.0%
N/A£889.64M£973.63MN/AN/A
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
2.3704 of 5 stars
GBX 663.98
-0.3%
GBX 792.50
+19.4%
+25.4%£543.27M£318M27.0034,300

Related Companies and Tools


This page (LON:BXP) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners